ArticleMycotoxin research2026
Investigation on Patulin biotransformation in Zebrafish and its toxicological function evaluation.
Article in Mycotoxin research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Patulin (PAT) is a mycotoxin that poses a significant health risk to both humans and animals. However, knowledge regarding its in vivo biotransformation and toxicological effects remains limited. In this study, zebrafish were exposed to a lethal dose of PAT for 24 h. Metabolite profiles in the intestine and liver were analyzed using UHPLC-Q-Orbitrap-HRMS, and toxicological effects were evaluated via histopathological examination, oxidative stress assays, RT-qPCR of target genes, and 16 S rRNA sequencing of the gut microbiota. The key results are as follows: (1) In addition to forming PAT-GSH adducts in the liver, zebrafish can metabolize PAT into ascladiol and hydroascladiol in the intestine, with distinct tissue-specific distribution. The gut bacterium Lactobacillus may play a crucial role in this conversion process. (2) Quantitative analysis revealed that the levels of ascladiol and hydroascladiol peaked during the initial exposure stage and then declined sharply, followed by a rapid increase in PAT-GSH adduct accumulation. (3) PAT exposure also induced tissue inflammation, oxidative stress, upregulation of pro-inflammatory factors, and gut microbiota dysbiosis. Importantly, the severity of adverse effects in the intestine and liver was directly correlated with both the distribution of non-toxic metabolites (ascladiol and hydroascladiol) and the accumulation of PAT-GSH adducts. We hypothesize that the intestine acts as an initial defense barrier against PAT, but with prolonged exposure, disruption of the gut microbiota impairs this detoxification process. Consequently, excess unmetabolized PAT enters the liver via enterohepatic circulation, triggering hepatic inflammation and oxidative damage. These findings provide new insights into the in vivo modulation of PAT toxicity.
Indexed as
Identifiers
42461462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.